Article
Clinical Neurology
Samuel Frank, Claudia Testa, Mary C. Edmondson, Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine O'Neill, Christina Vaughan, Jacquelyn Whaley, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola
Summary: This study evaluated the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease. The results showed that adverse events observed with long-term deutetrabenazine exposure were consistent with previous studies. Reductions in chorea persisted over time and there was no unexpected worsening of chorea upon treatment cessation.
Article
Pharmacology & Pharmacy
Kendall Curtis, Victor Sung
Summary: Huntington disease (HD) is a hereditary neurodegenerative disorder characterized by chorea. Deutetrabenazine is an effective and well-tolerated treatment for HD-associated chorea, with a longer half-life and reduced plasma fluctuations compared to tetrabenazine.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Clinical Neurology
Niaz Ahmed, Kennedy R. Lees, Rudiger von Kummer, Staffan Holmin, Irene Escudero-Martinez, Matteo Bottai, Olav Jansen, Nils Wahlgren
Summary: The SITS Open trial demonstrated that thrombectomy is superior to standard care for patients with large artery occlusion stroke in clinical practice. Results showed a significant shift in modified Rankin Scale at 3 months favoring the thrombectomy group.
Article
Dermatology
D. Wilsmann-Theis, C. Kromer, S. Gerdes, C. Linker, N. Magnolo, R. Sabat, K. Reich, R. Mossner
Summary: The study investigated the efficacy of apremilast in treating palmoplantar pustulosis (PPP) and found that 20 weeks of oral treatment resulted in significant improvement in both objective and subjective disease parameters, with minimal adverse events.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Stephanie Knatz Peck, Samantha Shao, Tessa Gruen, Kevin Yang, Alexandra Babakanian, Julie Trim, Daphna M. Finn, Walter H. Kaye
Summary: This open-label feasibility study explored the safety, tolerability and acceptability of using synthetic psilocybin in conjunction with psychological support for female anorexia nervosa patients. The results showed no clinically significant changes in vital signs, electrocardiogram or suicidality, indicating that psilocybin therapy may be a promising treatment option.
Article
Multidisciplinary Sciences
Kevin C. Kemp, Anastasia Georgievskaya, Kelly Hares, Juliana Redondo, Steven Bailey, Claire M. Rice, Neil J. Scolding, Chris Metcalfe, Alastair Wilkins
Summary: This pilot study investigates the potential therapeutic effects of recombinant granulocyte-colony stimulating factor (G-CSF) administration in patients with Friedreich's ataxia (FA). The findings demonstrate that G-CSF treatment is safe in FA patients, and it leads to mobilization of hematopoietic stem cells (HSCs) comparable to that of healthy individuals. Moreover, G-CSF administration results in sustained increases in cellular frataxin concentrations and elevated expression of PGC-1 alpha and Nrf2, indicating its potential clinical impact in FA patients.
NATURE COMMUNICATIONS
(2022)
Article
Clinical Neurology
Adem T. Can, Daniel F. Hermens, Abdalla Z. Mohamed, Zack Y. Shan, Megan Dutton, Cyrana Gallay, Grace Forsyth, Daniel Jamieson, Jim Lagopoulos
Summary: This study investigates the immediate and prolonged changes in resting-state neural networks after treatment with ketamine, to understand its therapeutic effects. The results show that ketamine can alter brain network connectivity, reduce suicide ideation, and support its use as a treatment for suicidal tendencies.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Microbiology
Erica L. Plummer, Lenka A. Vodstrcil, Michelle Doyle, Jennifer A. Danielewski, Gerald L. Murray, Glenda Fehler, Christopher K. Fairley, Dieter M. Bulach, Suzanne M. Garland, Eric P. F. Chow, Jane S. Hocking, Catriona S. Bradshaw
Summary: Initial treatment with antibiotics for bacterial vaginosis (BV) has a high rate of recurrence in women. A pilot study on heterosexual couples showed that concurrent partner treatment significantly reduced BV-associated bacteria in women and altered the genital microbiota composition in both partners. This approach may be a promising strategy to improve long-term BV cure rates.
Article
Psychiatry
Adem T. Can, Daniel F. Hermens, Megan Dutton, Cyrana C. Gallay, Emma Jensen, Monique Jones, Jennifer Scherman, Denise A. Beaudequin, Cian Yang, Paul E. Schwenn, Jim Lagopoulos
Summary: Oral ketamine treatment for chronic suicidality showed a significant reduction in suicidal ideation after 6 weeks, with 69% of participants achieving clinical improvement within the first 6 weeks. This suggests that oral administration could be a feasible and tolerable alternative treatment option for chronic suicidality, with results consistent with IV ketamine trials.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Rheumatology
Satoshi Ebata, Ayumi Yoshizaki, Koji Oba, Kosuke Kashiwabara, Keiko Ueda, Yukari Uemura, Takeyuki Watadani, Takemichi Fukasawa, Shunsuke Miura, Asako Yoshizaki-Ogawa, Naoko Okiyama, Masanari Kodera, Minoru Hasegawa, Shinichi Sato
Summary: Rituximab is a safe and effective treatment option for improving skin thickening in patients with systemic sclerosis, with sustained benefits for at least 48 weeks.
LANCET RHEUMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Marco Ceccanti, Laura Libonati, Gabriele Ruffolo, Pierangelo Cifelli, Federica Moret, Vittorio Frasca, Eleonora Palma, Maurizio Inghilleri, Chiara Cambieri
Summary: By conducting clinical tests and electrophysiological monitoring on 15 patients with anti-AChR myasthenia gravis, it was found that oral administration of 3,4-DAP had a significant effect in reducing disability level and muscle response decrement, especially in severe patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo, Manuela Telles, Rodrigo P. Mello, Flavia Vieira, Cassio S. Lima, Ana Paula Jesus-Nunes, Livia N. F. Guerreiro-Costa, Roberta F. Marback, Ana Teresa Caliman-Fontes, Breno L. S. Marques, Marilia L. O. Bezerra, Alberto L. Dias-Neto, Samantha S. Silva, Aline S. Sampaio, Gerard Sanacora, Gustavo Turecki, Colleen Loo, Acioly L. T. Lacerda, Lucas C. Quarantini
Summary: Arkamine may have the potential to rapidly produce sustained antidepressant effects with favorable safety profile in treating treatment-resistant depression. However, further controlled trials are needed to confirm its efficacy.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2021)
Article
Multidisciplinary Sciences
Sarah Buergler, Dilan Sezer, Alexander Busch, Marlon Enzmann, Berfin Bakis, Cosima Locher, Niels Bagge, Irving Kirsch, Claudia Carvalho, Jens Gaab
Summary: The study explored the experiences of test anxious students with an imaginary pill intervention, finding that it was well-accepted, easily applicable, and produced various beneficial effects. This approach could serve as an alternative to open-label placebos, warranting further investigation into its application to leverage placebo effects without a physical pill.
Article
Biochemistry & Molecular Biology
Angela Genchi, Elena Brambilla, Francesca Sangalli, Marta Radaelli, Marco Bacigaluppi, Roberto Furlan, Annapaola Andolfo, Denise Drago, Cinzia Magagnotti, Giulia Maria Scotti, Raffaella Greco, Paolo Vezzulli, Linda Ottoboni, Marco Bonopane, Daniela Capilupo, Francesca Ruffini, Daniela Belotti, Benedetta Cabiati, Stefania Cesana, Giada Matera, Letizia Leocani, Vittorio Martinelli, Lucia Moiola, Luca Vago, Paola Panina-Bordignon, Andrea Falini, Fabio Ciceri, Anna Uglietti, Maria Pia Sormani, Giancarlo Comi, Mario Alberto Battaglia, Maria A. A. Rocca, Loredana Storelli, Elisabetta Pagani, Giuseppe Gaipa, Gianvito Martino
Summary: This study conducted a phase 1 clinical trial evaluating the feasibility, safety and tolerability of intrathecally transplanted human fetal neural precursor cells (hfNPCs) in patients with progressive multiple sclerosis (PMS). The results demonstrated that hfNPC therapy is feasible, safe and tolerable in PMS patients.
Article
Dermatology
Koen Dudink, Klasiena Bouwman, Yanqing Chen, Samuel E. DePrimo, Ernesto J. Munoz-Elias, Pim Aarts, Renske Schappin, Edwin F. Florencia, Bennie van Heeswijk, Lisette M. Prens, Hessel H. van der Zee, Errol P. Prens, Kelsey R. van Straalen, Barbara Horvath
Summary: 65% of patients with moderate-to-severe hidradenitis suppurativa achieved a clinical response after 16 weeks of guselkumab treatment, which was well tolerated. Transcriptomic data supported the rationale for IL-23 inhibition with guselkumab, but did not consistently correlate with protein expression and clinical responses. Guselkumab seems to be beneficial only in a subgroup of HS patients, suggesting that the IL-23/T helper 17 axis is not central to the pathophysiology of HS.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Health Care Sciences & Services
Margaret O. Johnson, Samuel Frank, Matthew Mendlik, David Casarett
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
(2018)
Article
Biochemistry & Molecular Biology
Ji-Hyun Lee, Jong-Min Lee, Eliana Marisa Ramos, Tammy Gillis, Jayalakshmi S. Mysore, Shotaro Kishikawa, Tiffany Hadzi, Audrey E. Hendricks, Michael R. Hayden, Patrick J. Morrison, Martha Nance, Christopher A. Ross, Russell L. Margolis, Ferdinando Squitieri, Cinzia Gellera, Estrella Gomez-Tortosa, Carmen Ayuso, Oksana Suchowersky, Ronald J. Trent, Elizabeth McCusker, Andrea Novelletto, Marina Frontali, Randi Jones, Tetsuo Ashizawa, Samuel Frank, Marie-Helene Saint-Hilaire, Steven M. Hersch, Herminia D. Rosas, Diane Lucente, Madaline B. Harrison, Andrea Zanko, Ruth K. Abramson, Karen Marder, Jorge Sequeiros, G. Bernhard Landwehrmeyer, Ira Shoulson, Richard H. Myers, Marcy E. MacDonald, James F. Gusella
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2012)
Review
Clinical Neurology
Samuel Frank, William Ondo, Stanley Fahn, Christine Hunter, David Oakes, Sandra Plumb, Frederick Marshall, Ira Shoulson, Shirley Eberly, Francis Walker, Stewart Factor, Vicki Hunt, Aileen Shinaman, Joseph Jankovic
CLINICAL NEUROPHARMACOLOGY
(2008)
Review
Pharmacology & Pharmacy
Samuel Frank, Joseph Jankovic
Article
Clinical Neurology
Scott Y. H. Kim, Raymond De Vries, Robert G. Holloway, Renee Wilson, Sonali Parnami, H. Myra Kim, Samuel Frank, Karl Kieburtz
MOVEMENT DISORDERS
(2012)
Article
Clinical Neurology
Scott Y. H. Kim, Renee M. Wilson, H. Myra Kim, Robert G. Holloway, Raymond G. De Vries, Samuel A. Frank, Karl Kieburtz
MOVEMENT DISORDERS
(2012)
Article
Clinical Neurology
Michael D. Perloff, Jose-Rafael P. Zuzuarregui, Samuel A. Frank
Article
Clinical Neurology
Ari J. L. Wilkenfeld, Samuel A. Frank, David C. McCarthy
Editorial Material
Clinical Neurology
Samuel Frank
NATURE CLINICAL PRACTICE NEUROLOGY
(2009)
Review
Clinical Neurology
Samuel Frank
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2010)
Article
Clinical Neurology
Samuel Frank, Claudia Testa, Mary C. Edmondson, Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine O'Neill, Christina Vaughan, Jacquelyn Whaley, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola
Summary: This study evaluated the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease. The results showed that adverse events observed with long-term deutetrabenazine exposure were consistent with previous studies. Reductions in chorea persisted over time and there was no unexpected worsening of chorea upon treatment cessation.
Article
Clinical Neurology
Idaira Rodriguez Santana, Samuel Frank, Maria Doherty, Rosa Willock, Jamie Hamilton, Hayley Hubberstey, Cath Stanley, Louise Vetter, Michaela Winkelmann, Ricardo E. Dolmetsch, Nanxin Li, Sarah Ratsch, Talaha M. Ali
Summary: The study investigated the impact of Huntington's disease on health-related quality of life and patient-reported outcomes, providing new insights into the characteristics and burden of the disease.
NEUROLOGY-CLINICAL PRACTICE
(2022)
Article
Behavioral Sciences
Luis A. Sierra, Clementina J. Ullman, Samuel A. Frank, Simon Laganiere
Summary: The LASSI-L is a sensitive instrument for detecting early cognitive decline in individuals with preHD and outperforms commonly used neuropsychological tests.
COGNITIVE AND BEHAVIORAL NEUROLOGY
(2023)
Article
Medicine, Research & Experimental
Samuel Frank, Sarah Berk, Laura Hernandez, Penelope Hogarth, Holly A. Shill, Bernadette Siddiqi, David K. Simon
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2019)